Quest Diagnostics will begin offering Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) assay. This is the first and only FDA-cleared blood test designed to assess amyloid pathology, a primary indicator of Alzheimer's disease.
The test allows physicians to evaluate Alzheimer's risk through a standard blood draw. This approach provides a less invasive and more cost-effective alternative to traditional spinal taps or PET scans.
Clinicians will use the tool to identify candidates for new Alzheimer's therapies and clinical trials. The test helps rule in or rule out amyloid pathology for patients experiencing cognitive decline.
Quest will launch the service under its AD-Detect portfolio in the fourth quarter of 2026. The test will be available to physicians and clinical trial collaborators throughout the United States.